Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Gilead Sciences formed two partnerships in the final weeks of 2018. The firm is collaborating with Scholar Rock to develop antibodies that inhibit transforming growth factor (TGF) to treat fibrotic diseases. Scholar Rock will earn $80 million up front and up to $1.45 billion more depending on the success of three TGF programs. Separately, Gilead is paying Agenus $150 million to develop up to five cancer immunotherapies, including two bispecific antibodies. Agenus could earn up to $1.7 billion in milestones.
This article has been sent to the following recipient: